Dishman Carbogen Amcis Ltd

Stage 4 · Declining · week 14

As of 20 Nov 2026, Dishman Carbogen Amcis is in Stage 4, the downtrend phase, now in week 14 (since 11 Aug 2026). It closed at ₹116, 56.4% below its 52-week high and below its 200-day average, which is falling. In Health Care, 34.7% of stocks are in Stage 2.

Dishman Carbogen Amcis Limited provides contract research and manufacturing services for the pharmaceutical and healthcare industries worldwide. More about the company

₹115.6
Close, 20 Nov 2026
-2.50% on the day
₹1,812 Cr · Small cap
Market DowntrendHealth Care 34.7% in Stage 2-11.4 pts / 20dLabs & Life Sciences Services 33.3%0.0 pts

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

RS rank

Edge

—

DCAL is in a decline, 34% below its 200-day average. Declining stocks have lagged the market more than any other group; we wait for a base before looking again.

Its relative strength is 5 of 99, below the middle among NSE stocks over the past year. Labs & Life Sciences Services ranks 70 of 106 industries by the strength of its stocks.

Is DCAL early, or has it already run? Pro answers that for every NSE stock, after every close.

Loading price chart…
Stage Cycle Timeline2023-08-24 → 2026-11-20
S2 24w
S4 20w
S4 15w
2023-08-242026-11-20
S1S2S3S4Setup score (0–10, dashed line at 5)
S2 10w → S3 4w → S2 24w → S3 6w → S4 7w → S1 11w → S4 2w → S1 2w → S2 10w → S3 10w → S4 4w → S1 1w → S2 11w → S3 3w → S2 11w → S3 6w → S4 20w → S1 11w → S4 15w current
Total tracked: 168 weeks across 19 stage runs.

DCAL among Labs & Life Sciences Services6th of 6 by relative strength

All 6 →
Stocks in Labs & Life Sciences Services ranked by relative strength, with stage and one-month change
#StockStageRS1M
1DIVISLABStage 2 · wk 2693+21.7%
2AARTIPHARMStage 2 · wk 1384+17.5%
3VIMTALABSStage 3 · wk 530−4.3%
4SYNGENEStage 1 · wk 123+20.0%
5BROOKSStage 1 · wk 316+10.6%
6DCALStage 4 · wk 145−18.7%
vs 52W High
-56.4%
₹115.6 lo₹265 hi
56.4% below 52W high, deep Stage 4 damage
In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.
Stage Maturity
Week 14
1w13w26w
Week 14, established downtrend
How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.
vs 200 DMA
-33.8%
200 DMA: ₹174.7 · sloping down
The stock is below its 200-day average, the mark of a downtrend. Stage analysis waits for the price to reclaim that line.
Rel Volume
2.41x
vs 50-day avg
Volume ran well above average on a down day. In Stage 4 that points to continued institutional selling.
Trend Health
→
Short-term trend flat
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
-18.7%
3M
-33.0%
6M
-45.3%
YTD
-53.3%
1Y
-53.0%
Sector
Health Care
↓ Peaking
Stage 2%
34.7%
20d Δ
-11.4pp
1M return
+11.5%
3M return
+3.8%
Sector Stage-2 % · last 20 days
Sector has 58 Stage 2 leaders. See Health Care Stage 2 →
Industry
Labs & Life Sciences Services
→ Flat
Stage 2%
33.3%
20d Δ
+0.0pp
1M return
+20.9%
3M return
+27.9%
Industry Stage-2 % · last 20 days
Industry has 2 Stage 2 leaders. See Labs & Life Sciences Services Stage 2 →

Mutual fund holdings

Held by 4 mutual funds in portfolios to October 2026: 0 active funds and 4 index funds and ETFs.

In October, no active fund changed its holding.

All 4 funds and what each did in October

Mutual funds holding DCAL: the ten largest and the month’s moves →

Fund details on DiscoverMF

Scan Membership
Not in any scan now.
Last appeared 9 Sep 2025
Recent Stage Timeline
2026-11-20S4
Wk 14 · Vol 2.41x
2026-11-19S4
Wk 14 · Vol 5.21x
2026-11-18S4
Wk 14 · Vol 6.58x
2026-11-17S4
Wk 14 · Vol 7.76x
2026-11-16S4
Wk 14 · Vol 11.68x
2026-11-13S4
Wk 13 · Vol 0.76x
2026-11-12S4
Wk 13 · Vol 1.05x
2026-11-11S4
Wk 13 · Vol 2.22x
2026-11-09S4
Wk 13 · Vol 4.61x
2026-11-06S4
Wk 13 · Vol 0.43x
2026-11-05S4
Wk 12 · Vol 0.63x
2026-11-04S4
Wk 12 · Vol 0.55x
Moving averages & range
50 DMA
₹154.2
200 DMA
₹174.7
52W High
₹265
52W Low
₹115.6
5D Low
₹115.6
Resistance levels (recent highs)
20d High
₹175
60d High
₹181.8
120d High
₹199.1
250d High
₹265
Next resistance
+51.4%
to 20d High
P/E (TTM)
167.9
Forward 13.8
Earnings Growth (YoY)
-49.5%
Revenue -4.3%
ROE
+1.6%
Profit margin +0.6%
Dividend Yield
0.00%
P/B 0.4

Dishman Carbogen Amcis: quick answers

What stage is Dishman Carbogen Amcis in?

As of 20 Nov 2026, Dishman Carbogen Amcis (DCAL) is in Stage 4, the downtrend phase. It entered Stage 4 on 11 Aug 2026 and is in week 14. What the four stages mean

Is Dishman Carbogen Amcis in an uptrend?

No. Dishman Carbogen Amcis is in a Stage 4 downtrend. It trades 33.8% below its 200-day average, which is falling.

How far is Dishman Carbogen Amcis from its 52-week high?

Dishman Carbogen Amcis closed at ₹116 on 20 Nov 2026, 56.4% below its 52-week high of ₹265. Its 52-week low is ₹116.

How has Dishman Carbogen Amcis performed over the past year?

As of 20 Nov 2026, Dishman Carbogen Amcis is down 53.0% over the past year and down 53.3% so far in 2026.

Which sector and industry is Dishman Carbogen Amcis in?

Dishman Carbogen Amcis is in the Labs & Life Sciences Services industry, part of the Health Care sector. 61 stocks in Health Care are in Stage 2, 34.7% of the sector. See the Stage 2 stocks in Health Care

About this companyHealth Care· Labs & Life Sciences Services

Dishman Carbogen Amcis Limited provides contract research and manufacturing services for the pharmaceutical and healthcare industries worldwide. The company operates through Contract Research and Manufacturing Services and Marketable Molecules segments. It offers cholesterol and vitamin D analogs; generic active pharmaceutical ingredients for diagnostics, ophthalmic treatments, laxatives, organophosphate antidotes; ammonium, phosphonium; quats, phosphoranes, and wittig reagents; cholesterol and lanolin-related products; sterile injectables; and softgel formulations, as well as hand and body wash, sanitisers, and antiseptics. The company was founded in 1983 and is headquartered in Ahmedabad, India. Dishman Carbogen Amcis Limited is a subsidiary of Adimans Technologies LLP.

Visit company website →

All analytics based on EOD data. Data as of 2026-11-20. Past data patterns are not indicative of future results. This page is a data analytics tool only.